Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 4/20 | 0.31 |
| ▸ | CES1 | P23141 | 4/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137959 | 0.96 | CA1 (0.33) | EPHX1ALOX5PTGES | |
| SCHEMBL2133934 | 0.92 | — | — | |
| SCHEMBL2135881 | 0.91 | MAPT (0.36) | MAPTZDHHC7EPHX1FAAHCES1 | |
| SCHEMBL2135998 | 0.91 | MAPT (0.36) | MAPTZDHHC7EPHX1ALOX5ATM | |
| SCHEMBL2136109 | 0.90 | MAPT (0.32) | MAPTEPHX2NOD1ZDHHC7EPHX1 | |
| SCHEMBL2134448 | 0.90 | ZDHHC7 (0.40) | MAPTZDHHC7EPHX1MEN1KMT2A | |
| SCHEMBL2131308 | 0.89 | EPHX1 (0.32) | MAPTEPHX1 | |
| SCHEMBL2134690 | 0.88 | LMNA (0.35) | MAPTZDHHC7EPHX1FAAHCES1 | |
| SCHEMBL2132854 | 0.88 | ZDHHC7 (0.33) | MAPTEPHX2NOD1ZDHHC7EPHX1 | |
| SCHEMBL2140975 | 0.87 | MAPT (0.32) | MAPTZDHHC7EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664613-A1 | Process for producing amide compounds | Sumitomo Chemical Company, Limited (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-2662355-A1 | Process for producing a (fluoroalkylthio) acetonitrile | Sumitomo Chemical Company, Limited (JP) | 2013-11-13 | — | — | EP | disclosed |
| EP-2465846-A1 | PROCESS FOR PREPARATION OF (FLUOROALKYLTHIO)ACETIC ACID ESTERS | Sumitomo Chemical Company, Limited (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | GRHPR, AKR7A2, FAR1 | MAPT 4195/4885EPHX2 1665/4885NOD1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.